Alopecia areata is a skin disease that makes you lose patches or large sections of hair on your scalp and body. It's not life-threatening, but it can be life-altering. Hair is a part of your identity.

If you have alopecia areata, you are probably no stranger to a roller coaster of emotions. It’s true that this condition isn’t life-threatening and doesn't cause physical pain. But it can ...

CKD and ESRD can have unpleasant cutaneous manifestations, including alopecia, but there are several helpful approaches to mitigating hair loss.

Significantly more adolescent patients receiving baricitinib had hair regrowth compared with patients receiving placebo.

Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 weeks. Hair regrowth seemed to persist after treatment cessation to week 36. ORLANDO ...

placebo in adults with severe alopecia areata, according to phase 3 data presented here. Oral ivarmacitinib significantly induced hair regrowth at 24 weeks compared with placebo in adults with ...

Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.

Q32 Bio has put a stop to a Phase II trial of its former lead renal disease candidate as it pivots focus over to its alopecia areata treatment, bempikibart, amid a corporate restructure and job cuts.

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36 ...